Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) are now recommended by the ADA for the treatment of T2D, according to the individual needs of the patient [6]
At Kona Integrative Health, we believe that successful weight loss is not just about shedding pounds, but also about improving overall health and well-being
27 investigated the effects of varying doses of liraglutide, ranging from 1.2 to 3 mg, in comparison to placebo and orlistat, expanding our understanding of the relationship between liraglutide and psychiatric outcomes
Beyond taste disturbances, tirzepatide may be associated with other oral and oropharyngeal symptoms that patients should be aware of, though these are not extensively documented in the prescribing information as common adverse effects
This neurological shift addresses a root cause of weight regain that diet and exercise alone often cannot overcome
The pen is the delivery system, and it maintains its own sterile environment